Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Molecular subtypes of pancreatic cancer
Eric A. Collisson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis
Jinyu Tang et al.
LABORATORY INVESTIGATION (2019)
Next-Generation Sequencing in Pancreatic Cancer
Gong-Qing Shen et al.
PANCREAS (2019)
Genetics of Familial and Sporadic Pancreatic Cancer
Laura D. Wood et al.
GASTROENTEROLOGY (2019)
Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis
Yan Stein et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Prashanth Rawla et al.
WORLD JOURNAL OF ONCOLOGY (2019)
Mutant p53 in cancer therapy-the barrier or the path
Xiang Zhou et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Kanaga Sabapathy et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
VCP/p97-Mediated Unfolding as a Principle in Protein Homeostasis and Signaling
Johannes van den Boom et al.
MOLECULAR CELL (2018)
Challenges in diagnosis of pancreatic cancer
Lulu Zhang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma
Heather K. Schofield et al.
JCI INSIGHT (2018)
Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy
Evguenia M. Alexandrova et al.
CELL DEATH AND DIFFERENTIATION (2017)
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
Jonas Cicenas et al.
CANCERS (2017)
The Interplay of Cofactor Interactions and Post-translational Modifications in the Regulation of the AAA+ ATPase p97
Petra Haenzelmann et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2017)
Targeting p97 to Disrupt Protein Homeostasis in Cancer
Pratikkumar Harsukhbhai Vekaria et al.
FRONTIERS IN ONCOLOGY (2016)
Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis
Daniel J. Anderson et al.
CANCER CELL (2015)
Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)
Han-Jie Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Ribosomal proteins: functions beyond the ribosome
Xiang Zhou et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2015)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Patricia A. J. Muller et al.
CANCER CELL (2014)
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Susann Weissmueller et al.
CELL (2014)
CRISPR-Cas systems for editing, regulating and targeting genomes
Jeffry D. Sander et al.
NATURE BIOTECHNOLOGY (2014)
Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway
William A. Freed-Pastor et al.
CELL (2012)
Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion
Cynthia R. Coffill et al.
EMBO REPORTS (2012)
Mutant p53: one name, many proteins
William A. Freed-Pastor et al.
GENES & DEVELOPMENT (2012)
Targeting Mutant p53 in Human Tumors
Brian D. Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Inhibition of STAT3 Signaling Pathway by Nitidine Chloride Suppressed the Angiogenesis and Growth of Human Gastric Cancer
Jing Chen et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system
Hemmo Meyer et al.
NATURE CELL BIOLOGY (2012)
The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks
Klara Acs et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
Aimee L. Jackson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
The C terminus of p53 binds the N-terminal domain of MDM2
Masha V. Poyurovsky et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss
Tamara Terzian et al.
GENES & DEVELOPMENT (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Ubiquitination and degradation of mutant p53
Natalia Lukashchuk et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Structure-function-rescue: the diverse nature of common p53 cancer mutants
A. C. Joerger et al.
ONCOGENE (2007)
Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability
Won Ho Yang et al.
NATURE CELL BIOLOGY (2006)
14-3-3σ, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma
HL Yang et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
BF El-Rayes et al.
INVESTIGATIONAL NEW DRUGS (2005)
Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma
S Yamamoto et al.
ANNALS OF SURGICAL ONCOLOGY (2004)
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
KP Olive et al.
CELL (2004)
Elevated expression of valosin-containing protein (p97) is associated with poor prognosis of prostate cancer
Y Tsujimoto et al.
CLINICAL CANCER RESEARCH (2004)
Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma
S Yamamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence
S Yamamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53
SY Fang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
